Precision BioSciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
DTIL Nasdaq 8731 http://precisionbiosciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Precision BioSciences Inc

Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates - Mar 9th, 2023 1:15 pm
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update - Mar 9th, 2023 12:00 pm
A Precision BioSciences, Inc. (NASDAQ:DTIL) insider increased their holdings by 38% last year - Mar 7th, 2023 11:33 am
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023 - Mar 2nd, 2023 12:00 pm
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes - Feb 24th, 2023 12:00 pm
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference - Feb 22nd, 2023 12:00 pm
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Feb 14th, 2023 12:00 pm
Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week - Jan 20th, 2023 1:13 pm
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones - Jan 9th, 2023 12:30 pm
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate - Jan 6th, 2023 12:00 pm
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting - Dec 10th, 2022 3:00 pm
Precision BioSciences Third Quarter 2022 Earnings: Beats Expectations - Nov 11th, 2022 3:04 pm
Precision BioSciences Announces Change to its Board of Directors - Nov 10th, 2022 10:00 pm
Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates - Nov 8th, 2022 1:25 pm
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 8th, 2022 12:00 pm
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting - Nov 3rd, 2022 1:40 pm
Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022 - Nov 2nd, 2022 11:00 am
Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) - Oct 26th, 2022 11:00 am
Precision BioSciences, Inc. (NASDAQ:DTIL) is definitely on the radar of institutional investors who own 49% of the company - Oct 25th, 2022 10:40 am
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress - Oct 11th, 2022 7:00 am